Latest / Logosofia no Dia a Dia / What Actually Happens to Your Lungs During Hard Exercise
Transcript
- [Prompt] custom: I'd love to talk about exercise induced asthma. This used to be treated with a preventative puff of | Hosts: corn, herman [Response] Corn: Daniel sent us this one — and it's the kind of prompt that lands because it's so specific to a lived experience. He says he's in good shape, but after a hard run he still gets hit with chest tightness and coughing. His doctor used to tell him, just take two puffs of the reliever before you exercise. That advice has quietly changed. Now Singulair is in the picture as a preventive option, but there's a tension here — the FDA slapped a boxed warning on montelukast back in twenty twenty for serious mental health side effects, and that made a lot of clinicians nervous about prescribing it. Meanwhile, newer guidelines position it as a first-line controller for exercise-induced bronchoconstriction. So the safety-versus-efficacy question isn't settled, and it directly affects how active people manage their own lungs. Herman: It's worth flagging right at the top — this is not a story about someone who's deconditioned or just needs to train harder. Daniel is describing a real physiological phenomenon that hits elite athletes at the same rate, sometimes higher. The paradigm shift here is genuinely interesting because it tracks with how we've come to understand what's actually happening inside the airway during heavy exercise. The old approach was basically: relax the smooth muscle with a beta-agonist and call it a day. The new approach says, wait, there's an inflammatory cascade being triggered by the exercise itself, and if you don't address that upstream, you're just playing whack-a-mole with symptoms. Corn: Which is a very Herman way of putting it — whack-a-mole with bronchoconstriction. But it does capture the problem. The reliever-only strategy was treating the downstream effect, not the cause. And the fact that Daniel can be in good cardiovascular condition and still experience this tells you something important: the trigger isn't about fitness level. It's about what happens to the airway lining when you move huge volumes of air through it. Herman: Exactly the right framing. So let's define what we're actually talking about, because the terminology matters here. Exercise-induced bronchoconstriction, or EIB, is a transient narrowing of the airways that's triggered specifically by exertion. It's distinct from someone who has poorly controlled persistent asthma that just happens to flare during exercise. Up to ninety percent of people with asthma also have EIB, but here's the kicker — about ten to fifteen percent of people without any asthma diagnosis at all still get EIB. And it's disproportionately common in elite athletes, especially winter sport athletes. Cross-country skiers, speed skaters, ice hockey players — some studies put the prevalence above fifty percent in those groups. Corn: It's not just an asthma problem. It's an airway stress problem that happens to overlap heavily with asthma. Herman: And the classic presentation is one of those diagnostic clues that's easy to miss if you don't know to look for it. Symptoms typically peak five to fifteen minutes after you stop exercising, not during the activity itself. You finish your run, you're cooling down, and then your chest gets tight. That post-exertion timing is a big differentiator. If someone's just out of shape, they're going to feel breathless during the effort, and it resolves pretty quickly when they stop. Vocal cord dysfunction tends to happen during exercise and resolves almost immediately. EIB has this delayed onset that catches people off guard. Corn: Which probably explains a lot of the "I thought I was just winded" stories. You stop running, you feel okay for a minute, and then it hits. That doesn't feel like asthma to most people — it feels like you're recovering weirdly. Herman: The old paradigm for managing it was straightforward. Pre-treat with a short-acting beta-agonist, a SABA, like albuterol, fifteen to twenty minutes before you exercise. Two puffs, go run, you're fine. And for a lot of people, that worked acutely. The problem is it masked what was actually driving the process. You'd get smooth muscle relaxation, the airway would open up, but the underlying inflammatory mechanism was still firing every time you exercised. Over time, that led to over-reliance on reliever inhalers, which we now know is associated with worse outcomes — more exacerbations, more emergency visits. The paradigm had to shift. Corn: That's the landscape Daniel's question sits inside. He's describing the old advice he got, and he's noticing that the new advice sounds different. To understand why the treatment changed, we need to get into what's actually happening in the airway during a hard workout — and it's not what most people think. Herman: Let's start with the two competing theories of what causes EIB, because this debate shaped decades of research and it's only really been settled in the last fifteen or twenty years. The first is the thermal or rewarming theory. The idea is that during heavy exercise, you're breathing large volumes of air that's usually cooler and drier than your body temperature. That rapid ventilation cools the airways. When you stop exercising, the airways rewarm quickly, and that causes vascular congestion — the blood vessels in the bronchial wall dilate and leak fluid, leading to edema and bronchoconstriction. It's a vascular rebound phenomenon. Corn: The airway gets cold, then it warms up too fast, and the plumbing overreacts. Herman: That was the dominant theory for a long time. But it had some problems. For one thing, if you take someone with EIB and have them breathe cold dry air at rest, you can trigger bronchoconstriction without any exercise at all. And if you have them breathe warm humid air during exercise, EIB is dramatically reduced. That doesn't fit neatly with a pure thermal model. Which brings us to the osmotic theory — and this is where the evidence has really converged. Corn: This is the one that explains why being in shape doesn't protect you. Herman: The osmotic theory, most closely associated with Sandra Anderson and her colleagues, goes like this. At rest, your nose does the job of conditioning the air you breathe — it warms it and humidifies it before it reaches your lower airways. But during heavy exercise, your minute ventilation can jump from maybe five to ten liters per minute at rest to a hundred, even two hundred liters per minute. Your nose simply cannot keep up. The lower airways are forced to take over the humidification job, and they're not designed for it. As that huge volume of dry air passes over the airway surface liquid, water evaporates from the lining. The osmolarity of that surface liquid starts to climb. Corn: You're basically desiccating the inside of your airways. Herman: That's exactly the right image. The airway surface liquid becomes more concentrated, more salty. Once the osmolarity rises above about three hundred and fifty milliosmoles, something critical happens. Mast cells that are sitting in the airway mucosa sense that osmotic shift and degranulate. They dump their contents — histamine, prostaglandins, and crucially, cysteinyl leukotrienes. These are lipid mediators, and they are among the most potent bronchoconstrictors in human physiology. Corn: How potent are we talking? Herman: On a molar basis, cysteinyl leukotrienes are about a thousand times more potent as bronchoconstrictors than histamine. Let that sink in. Histamine gets all the attention because of allergies and antihistamines, but in the airway, leukotrienes are the heavyweight champions. They cause sustained, powerful smooth muscle contraction, they increase mucus secretion, and they promote edema in the airway wall. It's a triple threat. Corn: The exercise itself — the sheer volume of air moving through the pipes — creates an osmotic stress that triggers a cellular alarm system. And the alarm system releases chemicals that are orders of magnitude more powerful than what most people think of when they hear "inflammatory response. Herman: This is why the SABA-only approach was incomplete. A short-acting beta-agonist like albuterol works by binding to beta-two receptors on airway smooth muscle and telling those muscles to relax. It's a direct bronchodilator. It will open the airway, and it does it fast. But it does nothing to stop the mast cells from degranulating. It does nothing to block the leukotrienes from binding to their receptors. It's like turning down the volume on the speakers without unplugging the amplifier. The signal is still blasting, you've just made it quieter at the output. Corn: It explains why someone like Daniel, who's in good shape, can still get symptoms. Cardiorespiratory fitness doesn't change the osmolarity of your airway surface liquid. It doesn't make your mast cells more stable. In fact, if you're an endurance athlete with a high training volume, you might be exposing your airways to more osmotic stress, not less, because your minute ventilation during training sessions is higher and you're doing it more frequently. Herman: That's a critical point. There's a paradoxical relationship here. Elite endurance athletes — cyclists, runners, cross-country skiers — they have incredibly high minute ventilation during training, sometimes for hours at a time. The repeated cycles of airway dehydration and rehydration may actually cause epithelial damage over time. Some researchers think EIB in elite athletes without underlying asthma represents a form of airway injury from repetitive osmotic stress, not classic allergic asthma. It's a different endotype with potentially different long-term implications. Corn: The "you're just out of shape" misdiagnosis is doubly wrong. First, because EIB happens to people at peak fitness. Second, because high-level training might actually increase your risk. Herman: The misdiagnosis persists for a reason. Mild EIB can be subtle. The drop in FEV1 — that's forced expiratory volume in one second — might only be ten to fifteen percent. Someone might just feel a little tight, a little cough, maybe they chalk it up to allergies or getting older or not warming up enough. They don't connect it to the osmotic cascade we just described. They certainly don't think "I need a spirometry challenge. Corn: Let's talk about that classic study you mentioned — Anderson and Daviskas in two thousand. They showed that inhaling hypertonic saline could mimic EIB in susceptible individuals. No exercise, no thermal changes, just an osmotic challenge to the airway. That was a big piece of evidence tipping the scales toward the osmotic theory. Herman: It was elegant work. The hypertonic saline challenge essentially recreates the osmotic conditions of exercise-induced hyperpnea without any of the confounding variables — no increased ventilation, no thermal shifts, no metabolic changes. If you give someone with EIB an aerosol of saltwater that's more concentrated than their airway surface liquid, their mast cells degranulate and they bronchoconstrict. That's hard to explain with the thermal theory. And it gave researchers a tool to study EIB in the lab without needing a treadmill and a metabolic cart. Corn: The threshold concept is worth underlining. Anderson's group identified that once airway surface liquid osmolarity crosses roughly three hundred and fifty milliosmoles, mast cells start firing. Below that threshold, they're stable. Above it, they degranulate. That's a binary switch, not a gradual slope. It explains why EIB can be so variable — on a humid day, you might stay below the threshold. On a cold dry day, you cross it quickly. Herman: It explains why warm-up matters, which is something we should come back to when we talk about practical strategies. A proper warm-up induces a refractory period where EIB is blunted for up to two hours. The mechanism isn't fully understood, but one theory is that the initial bout of exercise partially depletes the mast cell mediators, so there's less to release on the second bout. Another possibility is that it triggers protective prostaglandins that stabilize the mast cells. Either way, it's a real phenomenon with clinical utility. Corn: We've got the mechanism — osmotic stress, mast cell degranulation, leukotriene release, bronchoconstriction. And we've established that SABAs only address the last step in that chain. Which brings us to the obvious question: if leukotrienes are the main bad actor here, what happens when you block them? Herman: That brings us to montelukast, brand name Singulair. Montelukast is a leukotriene receptor antagonist — it blocks the CysLT1 receptor, which is the receptor that cysteinyl leukotrienes bind to. Unlike a SABA, which reverses bronchoconstriction after it's already happening, montelukast prevents the leukotrienes from ever triggering that constriction in the first place. It's upstream. Multiple randomized controlled trials have shown that montelukast reduces the maximal fall in FEV1 after exercise by forty to sixty percent, and it also shortens recovery time. It has a twenty-four hour duration of action, so one daily dose covers all your exercise sessions — no need to time puffs before a workout, no need to carry an inhaler on your run. Corn: That's a meaningful quality-of-life difference. If you're someone who exercises at different times of day, or spontaneously, the SABA timing requirement — fifteen to twenty minutes before exercise — is annoying. A once-daily pill that just works in the background is a different proposition. Herman: That adherence advantage shows up in real-world data. People are more likely to actually take a daily pill than to consistently pre-treat with an inhaler before every workout. But here's where the story gets complicated. In March twenty twenty, the FDA required a boxed warning for montelukast. This was based on post-marketing surveillance that linked the drug to neuropsychiatric events — agitation, aggression, depression, insomnia, suicidal thoughts, and in rare cases, completed suicide. The warning applies to all patients, not just those with pre-existing mental health conditions. And it specifically states that montelukast should not be first-line for allergic rhinitis, but it can still be used for asthma and EIB when the benefit justifies the risk. Corn: That's a heavy warning to drop on a medication that had been widely prescribed, including to children, for years. Herman: And as a retired pediatrician, I can tell you this changed the conversation in clinics overnight. Montelukast had been popular in pediatrics because it's an oral medication — no inhaler technique to teach, no spacer to clean, just a chewable tablet once a day. After the boxed warning, a lot of parents were understandably alarmed. Some clinicians stopped prescribing it entirely. Others took a more nuanced approach, which is what the guidelines support: assess the individual patient's risk, have a frank discussion, document the conversation, and monitor closely. Corn: The absolute risk of serious neuropsychiatric events appears to be low — best estimates put it under one percent. But the signal is real, and it's not just the nocebo effect or background noise. There are case reports of symptoms resolving within days of stopping the drug and recurring when it's restarted. That's a pretty clean causal signal. Herman: The mechanism isn't fully understood. Montelukast does cross the blood-brain barrier, and leukotriene receptors are expressed in the brain. There's some evidence that blocking them might affect neurotransmitter regulation or neuroinflammation pathways. But we don't have a clear mechanistic explanation, which makes the risk-benefit calculus harder — you can't predict who's going to have a problem. Corn: The clinical dilemma is this: for someone with mild intermittent EIB, maybe a pre-exercise SABA is still the right call. The risk of the boxed warning, even if it's small, isn't worth it for occasional symptoms. But for someone with frequent EIB — say, twice a week or more — or someone who finds the SABA timing inconvenient and ends up not using it consistently, montelukast offers superior control. The key is shared decision-making. You tell the patient about the warning, you start at a low dose, and you instruct them to stop immediately and call you if they notice mood changes, sleep disturbances, or anything that feels off. Herman: That's exactly the framework. And it's worth comparing the numbers directly. SABA pre-treatment reduces the maximal FEV1 drop after exercise by about fifty percent on average. Montelukast reduces it by about fifty to sixty percent. The magnitude of protection isn't dramatically different. The advantages of montelukast are the twenty-four hour coverage, the once-daily dosing, and the fact that it addresses the inflammatory cascade rather than just overriding the smooth muscle contraction. For the right patient, those advantages are substantial. Corn: Let's make this concrete with a case, because I think that helps people see how the tradeoff plays out in real life. Twenty-eight-year-old recreational runner, EIB confirmed by eucapnic voluntary hyperpnea challenge — that's the gold-standard diagnostic test where you breathe dry air at high flow rates to simulate exercise conditions. She was using albuterol before runs but still getting breakthrough symptoms during interval training, when her ventilation was highest. Switched to montelukast ten milligrams at night. Symptoms resolved within three days. Six months later, she noticed mild mood swings — nothing severe, but enough that she mentioned it. Discontinued the montelukast, mood normalized, EIB symptoms returned. That's the efficacy-versus-safety tradeoff in one patient. The drug worked beautifully for her lungs, but the CNS side effect, even mild, was enough to tip the scales. Herman: That case illustrates something important. The side effects don't have to be catastrophic to matter. Mild mood changes that affect your relationships or your work are a valid reason to stop. The boxed warning gets attention because of the severe outcomes, but the more common scenario is probably subtler — and that's why the "stop and call me" instruction is so important. Patients need to know what to watch for. Corn: There are also emerging alternatives worth mentioning, even though they're not first-line for most people. Inhaled corticosteroids remain the foundation for persistent asthma with EIB, but they take weeks to reach full effect — not ideal if your main problem is exercise-triggered symptoms and you don't have daily asthma otherwise. Mast cell stabilizers like cromolyn sodium can work, but they require dosing four times a day, which is a lot to ask. And the newer biologics — omalizumab, mepolizumab — they show promise for severe EIB, but they're reserved for patients with eosinophilic phenotypes and they're expensive. Herman: The practical reality for most active people with EIB is that the choice comes down to SABA pre-treatment versus daily montelukast, with the boxed warning as the deciding factor in the conversation. And that conversation should happen with a doctor who knows the evidence and can walk through it honestly. Corn: Given all of that — the mechanism, the treatment shift, the safety tradeoffs — what should someone actually do if they recognize themselves in Daniel's prompt? Let's make it practical. First, if you're experiencing chest tightness, coughing, or unusual shortness of breath five to fifteen minutes after exercise — especially if you feel fine during the activity — get formally tested. Don't accept "you're just out of shape" as an answer. Eucapnic voluntary hyperpnea or a standard exercise challenge with spirometry is the way to confirm EIB. It's objective, it's reproducible, and it rules out other things like vocal cord dysfunction or deconditioning. Herman: Second, if you're using a SABA before every workout, ask your doctor whether a daily leukotriene receptor antagonist like montelukast might be more appropriate. Have the conversation about the boxed warning. The risk is real but rare, and for many people the benefit of reliable, round-the-clock EIB control outweighs it. The key is informed consent — you should know what you're signing up for and what to watch for. Corn: Third, don't sleep on the non-pharmacologic strategies. A proper warm-up — ten to fifteen minutes of low-intensity exercise before you go hard — can induce that refractory period where EIB is blunted for up to two hours. Wearing a face mask or a scarf in cold weather helps by trapping heat and moisture, reducing the osmotic load on your lower airways. And during low-to-moderate intensity work, nasal breathing reduces the volume of unconditioned air hitting the lower airways. None of these replace medication when it's needed, but they're zero-risk adjuncts that actually work. Herman: That warm-up effect is one of those things that's been known in exercise physiology for decades but still doesn't make it into most clinical conversations. The refractory period is real — if you do a gentle jog before your intervals, your second bout of exercise will produce less bronchoconstriction than the first. It's not a cure, but it's a tool. Corn: We've covered the mechanism, the treatment shift, and the practical steps. But there's one big question that's still open, and it's where the research is heading. The osmotic theory explains the acute trigger beautifully, but why do some people develop EIB without having persistent asthma at all? Is that a distinct endotype with different long-term implications? Some researchers think EIB in elite athletes represents a form of airway injury from repetitive osmotic stress — not classic allergic asthma, but something closer to an overuse injury of the airway epithelium. If that's right, it would imply different treatment targets and maybe different long-term management strategies. Herman: There are some interesting things in the pipeline. Inhaled leukotriene receptor antagonists are in development — the idea being you could get the benefits of montelukast delivered directly to the airway, reducing systemic exposure and potentially reducing the neuropsychiatric risk. Bronchial thermoplasty, which uses radiofrequency energy to reduce airway smooth muscle mass, is being studied for severe EIB, though it's still experimental for that indication. The field is moving. Corn: Daniel's prompt lands at a interesting moment. The old advice — two puffs and go — worked for a lot of people, but it was incomplete. The new advice is more effective but comes with a real safety conversation. And the science underneath it all — the osmotic theory, the leukotriene cascade — explains why exercise is a distinct trigger, different from allergens or irritants or cold air alone. It's not about being out of shape. It's about what happens when you push a hundred liters of dry air per minute through tubes that evolved for a fraction of that. Herman: Now: Hilbert's daily fun fact. Hilbert: In nineteen ten, a British expedition passing through the Gilbert Islands — now Kiribati — witnessed an intense red aurora so unusual that the ship's naturalist initially logged it as a distant volcanic eruption. The red colour came from high-altitude oxygen emitting at six hundred and thirty nanometers, a wavelength that only appears during particularly energetic solar events. Corn: A volcanic eruption in the sky. That's one way to misread the physics. Herman: What exactly is exercise-induced bronchoconstriction, and how is it different from the asthma you might have had as a kid? The distinction matters because it changes how you think about treatment. EIB is a transient narrowing of the airways triggered specifically by exertion. It's not the same as having poorly controlled persistent asthma that happens to flare up when you exercise — though the two often coexist. Corn: Someone with persistent asthma might wheeze at rest, wake up at night with symptoms, react to allergens. EIB is more specific. The trigger is the exercise itself, and between episodes the airways can be completely normal. Herman: The prevalence numbers tell an interesting story. Up to ninety percent of people with asthma also have EIB. But here's what catches people off guard — about ten to fifteen percent of people without any asthma diagnosis at all still get EIB. It shows up disproportionately in elite athletes. Cross-country skiers, speed skaters, ice hockey players — some studies put the prevalence above fifty percent in those winter sport groups. These are people at peak cardiovascular fitness, and their airways are still doing this. Corn: Which is why the "you're just out of shape" thing is such a persistent misdiagnosis. If elite athletes get it, fitness isn't the variable. Herman: The classic presentation is one of those clinical clues that's easy to miss if nobody's told you about it. Symptoms typically peak five to fifteen minutes after you stop exercising, not during the activity itself. You finish your run, you're cooling down, you feel okay for a minute, and then your chest gets tight. That post-exertion timing is a key differentiator. Someone who's deconditioned feels breathless during the effort and it resolves quickly when they stop. Vocal cord dysfunction tends to happen during exercise and resolves almost immediately when the activity ends. EIB has this delayed onset. Corn: Which probably explains a lot of people thinking "that was a weird recovery" rather than "that was bronchoconstriction." It doesn't feel like what most people imagine asthma feels like. Herman: For decades, the management paradigm was simple. Pre-treat with a short-acting beta-agonist — albuterol, two puffs, fifteen to twenty minutes before you exercise. Go run, you're fine. And for a lot of people, that worked acutely. The problem was it masked what was actually driving the process. You'd get smooth muscle relaxation, the airway would open up, but the underlying inflammatory mechanism kept firing every time you exercised. Over time, that led to over-reliance on reliever inhalers, which we now know is associated with worse outcomes — more exacerbations, more emergency visits. The paradigm had to shift. Herman: To understand why the treatment shifted, we need to start with what's actually happening in the airway during a hard workout — and it's not what most people think. There are two competing theories of what causes EIB, and this debate shaped decades of research before the evidence really converged. Corn: Lay them out. Herman: The first is the thermal or rewarming theory. During heavy exercise, you're breathing large volumes of air that's usually cooler and drier than body temperature. That rapid ventilation cools the airways. When you stop, the airways rewarm quickly, and that causes vascular congestion — blood vessels in the bronchial wall dilate, leak fluid, and you get edema and bronchoconstriction. It's a vascular rebound phenomenon. Corn: The airway gets chilled, then it warms up too fast, and the plumbing overreacts. Herman: That was the dominant model for a long time. But it had gaps. If you take someone with EIB and have them breathe cold dry air at rest — no exercise, no metabolic demand — you can still trigger bronchoconstriction. And if you have them breathe warm humid air during exercise, EIB is dramatically reduced. Neither of those fits neatly with a pure thermal model. Corn: Which is where the osmotic theory comes in. Herman: This is where the evidence has really landed. The osmotic theory, most closely associated with Sandra Anderson and her group, goes like this. At rest, your nose handles air conditioning — it warms and humidifies every breath before it reaches the lower airways. But during heavy exercise, your minute ventilation jumps from maybe five to ten liters per minute at rest to a hundred, even two hundred liters per minute. Your nose simply cannot keep up with that volume. The lower airways are forced to take over the humidification job, and they're not built for it. As that huge volume of dry air passes over the airway surface liquid, water evaporates from the lining. The osmolarity of that surface liquid starts climbing. Corn: You're desiccating the inside of your airways. Herman: The airway surface liquid becomes more concentrated, more salty. Once the osmolarity rises above about three hundred and fifty milliosmoles, something critical happens. Mast cells sitting in the airway mucosa sense that osmotic shift and they degranulate. They dump their contents — histamine, prostaglandins, and crucially, cysteinyl leukotrienes. These are lipid mediators, and they are among the most potent bronchoconstrictors in human physiology. Herman: On a molar basis, cysteinyl leukotrienes are about a thousand times more potent than histamine. Histamine gets all the attention because of allergies and antihistamines, but in the airway, leukotrienes are the heavyweight champions. They cause sustained, powerful smooth muscle contraction, they ramp up mucus secretion, and they promote edema in the airway wall. It's a triple threat. Corn: The exercise itself — the sheer volume of air moving through the pipes — creates an osmotic stress that triggers a cellular alarm system. And that alarm releases chemicals orders of magnitude more powerful than what most people picture when they hear "inflammatory response. Herman: This is why the SABA-only approach was incomplete. Albuterol works by binding to beta-two receptors on airway smooth muscle and telling those muscles to relax. It's a direct bronchodilator, and it works fast. But it does nothing to stop the mast cells from degranulating. It does nothing to block leukotrienes from binding to their receptors. It's like turning down the volume on the speakers without unplugging the amplifier. The signal is still blasting — you've just made it quieter at the output. Corn: That's a good image. And it explains why someone like Daniel, who's in good shape, still gets symptoms. Cardiorespiratory fitness doesn't change the osmolarity of your airway surface liquid. It doesn't make your mast cells more stable. In fact, if you're an endurance athlete with high training volume, you might be exposing your airways to more osmotic stress, not less — your minute ventilation during training sessions is higher, and you're doing it more frequently. Herman: There's a paradoxical relationship here. Elite endurance athletes — cyclists, runners, cross-country skiers — have incredibly high minute ventilation during training, sometimes for hours at a time. The repeated cycles of airway dehydration and rehydration may actually cause epithelial damage over time. Some researchers think EIB in elite athletes without underlying asthma represents a form of airway injury from repetitive osmotic stress, not classic allergic asthma. It's a different endotype. Corn: The "you're just out of shape" misdiagnosis is doubly wrong. First, because EIB hits people at peak fitness. Second, because high-level training might actually increase your risk. Herman: The misdiagnosis persists because mild EIB can be subtle. The drop in FEV1 — forced expiratory volume in one second — might only be ten to fifteen percent. Someone feels a little tight, a little cough, chalks it up to allergies or getting older or not warming up enough. They don't connect it to the osmotic cascade. They certainly don't think "I need a spirometry challenge. Corn: The Anderson and Daviskas study in two thousand was the one that really tipped the scales. They showed that inhaling hypertonic saline could mimic EIB in susceptible individuals — no exercise, no thermal changes, just an osmotic challenge to the airway. That's hard to explain with the thermal theory. Herman: The hypertonic saline challenge recreates the osmotic conditions of exercise-induced hyperpnea without any confounding variables. If you give someone with EIB an aerosol of saltwater that's more concentrated than their airway surface liquid, their mast cells degranulate and they bronchoconstrict. It gave researchers a tool to study EIB in the lab without needing a treadmill and a metabolic cart. Corn: Anderson's group identified that threshold — once airway surface liquid osmolarity crosses roughly three hundred and fifty milliosmoles, mast cells start firing. Below that, they're stable. Above it, they degranulate. It's a binary switch, not a gradual slope. That explains why EIB can be so variable day to day. On a humid morning, you might stay below the threshold. On a cold dry day, you cross it fast. Herman: Which is also why warm-up matters, and we should come back to that when we talk practical strategies. A proper warm-up induces a refractory period where EIB is blunted for up to two hours. One theory is that the initial bout partially depletes mast cell mediators, so there's less to release on the second bout. Another is that it triggers protective prostaglandins that stabilize the mast cells. Either way, it's a real phenomenon with clinical utility. Corn: We've got the mechanism — osmotic stress, mast cell degranulation, leukotriene release, bronchoconstriction. And we've established that SABAs only address the last step in that chain. If leukotrienes are the main bad actor here, the obvious next question is what happens when you block them. Herman: That brings us to montelukast — brand name Singulair. It's a leukotriene receptor antagonist, which means it blocks the CysLT1 receptor, the exact docking site where those cysteinyl leukotrienes would normally bind and trigger bronchoconstriction. Unlike a SABA, which reverses the squeezing after it's already happening, montelukast prevents the leukotrienes from ever delivering the squeeze signal. It's upstream in a way that albuterol simply isn't. Corn: Instead of turning down the speakers, you're unplugging the amplifier before the signal even gets there. Herman: That's the idea. And the clinical trial data backs it up. Multiple randomized controlled trials show montelukast reduces the maximal fall in FEV1 after exercise by forty to sixty percent, and it shortens recovery time. It also has a twenty-four hour duration of action. One dose at night covers you for a run at six a., a swim at noon, and a pickup basketball game in the evening — no timing puffs, no carrying an inhaler. Corn: That's a real quality-of-life difference. If you exercise at unpredictable times, or you're the kind of person who decides to go for a run on a whim, the fifteen-to-twenty-minute pre-treatment window for albuterol is annoying. A pill you take before bed and forget about is a different proposition entirely. Herman: Adherence data reflects that. People are more likely to consistently take a daily pill than to reliably pre-treat with an inhaler before every workout. But this is where the story takes a sharp turn. In March twenty twenty, the FDA required a boxed warning for montelukast — the strongest warning they issue short of a recall. Post-marketing surveillance had linked it to neuropsychiatric events: agitation, aggression, depression, insomnia, suicidal thoughts, and in rare cases, completed suicide. The warning applies to all patients, not just those with pre-existing mental health conditions. Corn: That's a heavy thing to drop on a medication that had been prescribed widely for years, including to kids. Herman: As someone who prescribed this in practice, I can tell you it changed the conversation overnight. Montelukast had been popular in pediatrics precisely because it's an oral medication — no inhaler technique to teach, no spacer to clean, just a chewable tablet once a day. After the boxed warning, a lot of parents were understandably alarmed. Some clinicians stopped prescribing it entirely. Others took a more measured approach, which is what the guidelines support: assess the individual patient, have the frank discussion, document it, and monitor closely. Corn: The absolute risk of serious neuropsychiatric events appears low — best estimates put it under one percent. But the signal is real, and it's not just background noise. There are case reports of symptoms resolving within days of stopping the drug and recurring when it's restarted. That's a pretty clean causal signal, even if the mechanism isn't fully understood. Herman: The mechanism is unclear. Montelukast does cross the blood-brain barrier, and leukotriene receptors are expressed in the brain. There's some evidence that blocking them might affect neurotransmitter regulation or neuroinflammation pathways, but we don't have a crisp mechanistic explanation. That makes the risk-benefit calculus harder — you can't predict who's going to have a problem. Corn: The clinical dilemma shapes up like this. For someone with mild intermittent EIB — they get symptoms once every couple of weeks, maybe — a pre-exercise SABA is probably still the right call. The boxed warning risk, even if it's small, isn't worth it for occasional symptoms. But for someone with frequent EIB, twice a week or more, or someone who just won't consistently time their inhaler before exercise, montelukast offers superior control. The key is shared decision-making. You tell the patient about the warning, you start at a low dose, and you give them clear instructions: if you notice mood changes, sleep disturbances, or anything that feels off, stop the drug and call me. Herman: That's the framework. And let's compare the numbers directly. SABA pre-treatment reduces the maximal FEV1 drop after exercise by about fifty percent on average. Montelukast reduces it by about fifty to sixty percent. The magnitude of protection isn't dramatically different in absolute terms. The real advantages of montelukast are the twenty-four hour coverage, the once-daily dosing, and the fact that it addresses the inflammatory cascade rather than just overriding smooth muscle contraction. For the right patient, those advantages tip the scales. Corn: Let's make this concrete with a case, because the tradeoff gets clearer when you see it play out. Twenty-eight-year-old recreational runner, EIB confirmed by eucapnic voluntary hyperpnea challenge — that's the gold-standard diagnostic test, breathing dry air at high flow rates to simulate exercise conditions. She was using albuterol before runs but still getting breakthrough symptoms during interval training, when her ventilation was highest. Switched to montelukast ten milligrams at night. Symptoms resolved within three days. Six months later, she noticed mild mood swings — nothing severe, but enough that she mentioned it. Discontinued the montelukast, mood normalized, EIB symptoms returned. That's the efficacy-versus-safety tradeoff in one patient. The drug worked beautifully for her lungs, but the CNS side effect, even mild, was enough to tip the scales back. Herman: That case highlights something important. The side effects don't have to be catastrophic to matter. Mild mood changes that affect your relationships or your work are a valid reason to stop. The boxed warning gets attention because of the severe outcomes, but the more common scenario is probably subtler — which is why the "stop and call me" instruction is so critical. Patients need to know what to watch for. Corn: There are other options in the toolbox worth mentioning, even if they're not first-line for most people. Inhaled corticosteroids remain the foundation for persistent asthma with EIB, but they take weeks to reach full effect — not ideal if your main problem is exercise-triggered symptoms and you don't have daily asthma otherwise. Mast cell stabilizers like cromolyn sodium can work, but they require dosing four times a day, which is a lot to ask of someone who just wants to go for a run. And the newer biologics — omalizumab, mepolizumab — show promise for severe EIB, but they're reserved for patients with eosinophilic phenotypes and they're expensive. Herman: The practical reality for most active people with EIB is that the choice comes down to SABA pre-treatment versus daily montelukast, with the boxed warning as the deciding factor in the conversation. And that conversation should happen with a doctor who knows the evidence and can walk through it honestly — not someone who either dismisses the warning entirely or refuses to prescribe montelukast under any circumstances. Both of those extremes leave patients worse off. Corn: Given all of that — the mechanism, the treatment shift, the safety tradeoffs — what should someone actually do if they recognize themselves in Daniel's prompt? Let's make it practical. First, if you're experiencing chest tightness, coughing, or unusual shortness of breath five to fifteen minutes after exercise, especially if you feel fine during the activity, get formally tested. Don't accept "you're just out of shape" as an answer. Eucapnic voluntary hyperpnea or a standard exercise challenge with spirometry is the way to confirm EIB. It's objective, it's reproducible, and it rules out other things like vocal cord dysfunction or deconditioning. Herman: Second, if you're using a SABA before every workout, ask your doctor whether a daily leukotriene receptor antagonist like montelukast might be more appropriate. Have the conversation about the boxed warning. The risk is real but rare, and for many people the benefit of reliable, round-the-clock EIB control outweighs it. The key is informed consent — you should know what you're signing up for and what to watch for. Corn: Third, don't sleep on the non-pharmacologic strategies. A proper warm-up — ten to fifteen minutes of low-intensity exercise before you go hard — can induce that refractory period where EIB is blunted for up to two hours. Wearing a face mask or a scarf in cold weather helps by trapping heat and moisture, reducing the osmotic load on your lower airways. And during low-to-moderate intensity work, nasal breathing reduces the volume of unconditioned air hitting the lower airways. None of these replace medication when it's needed, but they're zero-risk adjuncts that actually work. Herman: That warm-up effect is one of those things that's been known in exercise physiology for decades but still doesn't make it into most clinical conversations. The refractory period is real — if you do a gentle jog before your intervals, your second bout of exercise will produce less bronchoconstriction than the first. It's not a cure, but it's a tool. Corn: We've covered the mechanism, the treatment shift, and what you can actually do about it. But there's one question that's still open, and it's where the research is heading. The osmotic theory explains the acute trigger beautifully — dry air, evaporative water loss, mast cell degranulation, leukotrienes, bronchoconstriction. But it doesn't explain why some people develop EIB without having persistent asthma at all. Is that a distinct endotype with different long-term implications? Herman: That's the question that's driving a lot of the current work. Some researchers think EIB in elite athletes — especially those without underlying allergic asthma — represents a form of airway injury from repetitive osmotic stress. It's not classic type two inflammation with eosinophils and IgE. It's more like an overuse injury of the airway epithelium. If that's right, it would imply different treatment targets and maybe different long-term management strategies than what we'd use for allergic asthma with EIB. Corn: Which matters, because if you're treating an overuse injury with anti-inflammatory drugs designed for allergic disease, you might be aiming at the wrong target. Herman: And there are some interesting things in the pipeline that might change the landscape. Inhaled leukotriene receptor antagonists are in development — the idea being you could deliver montelukast directly to the airway, get the same receptor blockade where you need it, but with much lower systemic exposure. If the neuropsychiatric effects are driven by the drug crossing the blood-brain barrier, an inhaled formulation could potentially sidestep that risk entirely. Corn: That would be a meaningful advance. The efficacy without the boxed warning conversation hanging over every prescription. Herman: Bronchial thermoplasty is also being studied for severe EIB, though it's still experimental for that indication. The procedure uses radiofrequency energy to reduce airway smooth muscle mass — it's already approved for severe persistent asthma. The logic for EIB would be that less smooth muscle means less capacity for bronchoconstriction, regardless of what's triggering it. But it's invasive, it's expensive, and the evidence base for EIB specifically is thin. Corn: For now, the practical landscape is what we laid out — SABA pre-treatment versus daily montelukast, informed by an honest conversation about the boxed warning, with non-pharmacologic strategies as a zero-risk complement either way. But the fact that the science is still evolving on the endotype question means the treatment paradigm might look different in five or ten years. Herman: That's the kind of thing that makes this topic worth revisiting as the evidence accumulates. Daniel's prompt landed at a moment where the old advice — two puffs and go — has been quietly replaced by something more nuanced, and the replacement is still being refined. Corn: If you have a weird prompt about your own body, your medications, or something you've always wondered about health and science, send it to prompts at my weird prompts dot com. We read every one. Herman: This has been My Weird Prompts, produced by Hilbert Flumingtop. Find us at my weird prompts dot com or wherever you get your podcasts. Corn: Until next time.